#United States #New York #Gross Law Firm #MLTX #MoonLake Immunotherapeutics

Gross Law Firm Reminds Shareholders of Key Deadline in MoonLake Lawsuit

The Gross Law Firm has issued an important notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Investors who purchased shares between March 10, 2024, and September 29, 2025, are encouraged to contact the firm regarding the possibility of being appointed as lead plaintiff in a class action lawsuit. The deadline for this is December 15, 2025, and it is crucial for shareholders to take action before this date.

Allegations Against MoonLake

The class action complaint alleges that during the specified period, the defendants made materially false and misleading statements while failing to disclose key information regarding the company’s drug candidate, SLK. Among the main allegations are the following:

1. Similar Molecular Targets: It is claimed that both SLK and BIMZELX, another drug, share the same molecular targets, which raises questions about the uniqueness of SLK.
2. Clinical Benefit: There are doubts about whether SLK’s unique Nanobody structure provides any superior clinical benefit compared to traditional monoclonal antibodies like BIMZELX.
3. Tissue Penetration Versus Clinical Efficacy: Despite assertions of improved tissue penetration by SLK, there are concerns that this will not translate into actual clinical efficacy.
4. Unfounded Positive Statements: The defendants allegedly lacked a reasonable basis for their positive claims regarding SLK's effectiveness compared to monoclonal antibodies.

These claims contribute to the seriousness of the allegations against the firm, and shareholders who have incurred losses might have grounds for participation in the class action.

Importance of Class Action Participation

It's important for shareholders to understand that appointing a lead plaintiff is not a prerequisite to participate in any recoveries that may arise from the lawsuit. By registering their information, shareholders will have access to portfolio monitoring software that gives regular updates on the case's status throughout its duration. Beyond just the financial implications, participating in class action lawsuits helps ensure that companies maintain transparency and accountability in their operations.

Next Steps for Investors

Investors who purchased shares of MLTX within the defined period should take action without delay. To register, shareholders can visit the Gross Law Firm's designated page and submit their details. The registration process is free of charge, addressing any potential hurdles for investors wishing to join the case.

This proactive approach serves to protect the rights of the shareholders and holds the company accountable for the claims made during the class period.

Why Choose the Gross Law Firm?

The Gross Law Firm has established itself as a leading class action and securities law firm, dedicated to safeguarding investors from dishonest practices in the market. The firm's commitment lies in ensuring that corporations follow ethical protocols in their communications and business practices. Its track record demonstrates a strong commitment to recovering losses incurred by investors when companies fail to deliver truthful disclosures.

For shareholders of MoonLake Immunotherapeutics, now is the time to assess your situation and decide to join the class action. The deadline of December 15, 2025, is approaching quickly, and taking action now could potentially lead to compensation for losses incurred during the class period.

For those with any questions or needing assistance, The Gross Law Firm can be reached at their office located at 15 West 38th Street, 12th floor, New York, NY, 10018. They can also be contacted via phone at (646) 453-8903 or through their website for further information.

Stay informed and take the necessary steps to protect your investment rights.